Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCX507-B safety, tolerability, pharmacokinetics, pharmacodynamics, and food-effect study in healthy volunteers
NL-OMON40895Active, not recruiting
- Sponsor
- ChemoCentryx
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of CCX507-B in Crohn's disease and inflammatory bowel disease (IBD) (6 arms), sponsored by ChemoCentryx. Primary endpoint: Safety and tolerability of single and multiple oral doses of CCX507-B. Started Mar 2014; status: active, not recruiting.
02
Drugs
CCX507-B
03
Conditions
Crohn's diseaseinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NL-OMON40895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40895.